According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are $0.76 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2022-12-31 | $0.66 B | -5.38% |
2021-12-31 | $0.69 B | 14.79% |
2020-12-31 | $0.60 B | -9.06% |
2019-12-31 | $0.66 B | 30.59% |
2018-12-31 | $0.51 B | 15.03% |
2017-12-31 | $0.44 B | 787.2% |
2016-12-31 | $50.2 M | -0.24% |
2015-12-31 | $50.33 M | 46.59% |
2014-12-31 | $34.33 M | 0.2% |
2013-12-31 | $34.26 M | -17.64% |
2012-12-31 | $41.6 M | -46.85% |
2011-12-31 | $78.28 M | -37.41% |
2010-12-31 | $0.12 B | 87.06% |
2009-12-31 | $66.86 M | -17.87% |
2008-12-31 | $81.4 M | -48.46% |
2007-12-31 | $0.15 B | 110.72% |
2006-12-31 | $74.96 M | -19.41% |
2005-12-31 | $93.01 M | -25.82% |
2004-12-31 | $0.12 B | -23.47% |
2003-12-31 | $0.16 B | 287.45% |
2002-12-31 | $42.28 M | 17.6% |
2001-12-31 | $35.95 M |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | $94.38 B | 12,316.92% | ๐บ๐ธ USA |
![]() AbbVie ABBV | $121.24 B | 15,850.66% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $43.66 B | 5,644.60% | ๐บ๐ธ USA |
![]() Repligen
RGEN | $0.57 B | -23.95% | ๐บ๐ธ USA |
![]() Athersys ATHX | $47.89 M | -93.70% | ๐บ๐ธ USA |
![]() ANI Pharmaceuticals ANIP | $0.42 B | -44.10% | ๐บ๐ธ USA |
![]() Palatin Technologies PTN | $16.01 M | -97.89% | ๐บ๐ธ USA |
![]() Royalty Pharma RPRX | $7.30 B | 861.43% | ๐ฌ๐ง UK |